Nvidia Drive AGX (NASDAQ:NVDA)
The Nvidia Drive AGX (NASDAQ:NVDA) platform now supports the MAVIN DR dynamic view lidar system from MicroVision (NASDAQ:MVIS). According to MAVIN DR, new ADAS safety features can provide the highway-pilot capabilities that OEMs seek since MAVIN DR reportedly offers good resolution at all ranges and with low latency.
The Nvidia Drive AGX platform provides performance for the development and manufacture of functionally safe AI-powered cars, trucks, robotaxis, and more. It acts as the AI brain for highly automated and fully self-driving vehicles. Just about 2 PM ET, MVIS shares were up 2%.
A Review of the MicroVision prognosis
Shares of MicroVision surged during the 2021 meme stock craze. MicroVisions fundamentals, however, continue to be unimpressive, and shares seem to be unduly overpriced. When sales are so low, MicroVision must turn to perpetual share dilution to maintain operations.
In contrast to its predicted revenues of less than $2 million for 2022, MicroVision has a market cap of $845 million. Over the past ten years, the company hasnt generated an operating profit even once. And its previous product introductions have frequently disappointed.
Outlook for the MVIS Stock
Some American Electronic analysts predict that MicroVision will soon reach breakeven. According to their forecast, the company would post its final loss in 2023 before turning a $92 million profit the following year. As a result, the breakeven point for the business is predicted to occur in about two years.
What rate of annual growth would the business need to reach breakeven on this date? Simply Wall Streets statistics indicate a relatively optimistic average yearly growth rate of 57%. If it turns out that this rate is too high, the company might not reach profitability as soon as analysts had predicted.
Featured Image- Megapixl @Andreistanescu
Author: Jowi Kwasu
Market Jar Media Inc.
#170 – 422 Richards Street
Vancouver, BC, Canada
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Digital Health journalist was involved in the writing and production of this article.